Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

Autor: de Bono JS; The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@irc.ac.uk., Concin N; BGOG and Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium., Hong DS; Phase I Unit, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thistlethwaite FC; Department of Medical Oncology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Machiels JP; Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain, Brussels, Belgium., Arkenau HT; Sarah Cannon Research Institute, University College of London, London, UK., Plummer R; Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle University, Newcastle, UK., Jones RH; Velindre Cancer Centre and Cardiff University, Cardiff, UK., Nielsen D; Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Cophenhagen, Denmark., Windfeld K; Genmab, Copenhagen, Denmark., Ghatta S; Genmab US, Princeton, NJ, USA., Slomovitz BM; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Spicer JF; Guy's Hospital, King's College London, London, UK., Yachnin J; Karolinska University Hospital, Solna, Sweden., Ang JE; The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Mau-Sørensen PM; Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark., Forster MD; UCL Cancer Institute, University College London Hospitals, London, UK., Collins D; Department of Medical Oncology, Cork University Hospital, Cork, Ireland., Dean E; Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain, Brussels, Belgium., Rangwala RA; Genmab US, Princeton, NJ, USA., Lassen U; Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2019 Mar; Vol. 20 (3), pp. 383-393. Date of Electronic Publication: 2019 Feb 08.

Progress in Gynecologic Cancers with Antibody Drug Conjugates.

Autor: O'Malley, David M., Calo, Corinne A.

Publikováno v: Current Oncology Reports; Aug2021, Vol. 23 Issue 8, p1-11, 11p

New Research on Hematological Malignancies

Autor: David K. Gioia

Hematological malignancies, defined as cancers that affect the blood, bone marrow, and lymph nodes, represent a serious health care challenge for oncologists. Chapter One focuses on cytogenetic and molecular markers and summarizes their importance in